Cargando…

Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study

BACKGROUND: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with b...

Descripción completa

Detalles Bibliográficos
Autores principales: Guilleminault, Laurent, Camus, Claire, Raherison-Semjen, Chantal, Capdepon, Audrey, Bourdin, Arnaud, Bonniaud, Philippe, Fry, Stéphanie, Devouassoux, Gilles, Blanc, François-Xavier, Pison, Christophe, Dupin, Clairelyne, Khayath, Naji, Courdeau, Joelle, Valcke-Brossollet, Judith, Nocent-Ejnaini, Cécilia, Rolland, Fabien, Lamandi, Carmen, Proust, Alain, Ozier, Anaig, Portel, Laurent, Gaspard, Wanda, Roux-Claude, Pauline, Beurnier, Antoine, Martinez, Stéphanie, Dot, Jean-Marc, Hennegrave, Florence, Vignal, Guillaume, Auvray, Etienne, Paleiron, Nicolas, Just, Nicolas, Miltgen, Jean, Russier, Maud, Olivier, Cécile, Taillé, Camille, Didier, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655663/
https://www.ncbi.nlm.nih.gov/pubmed/37966015
http://dx.doi.org/10.1177/17534666231202749
_version_ 1785147972132012032
author Guilleminault, Laurent
Camus, Claire
Raherison-Semjen, Chantal
Capdepon, Audrey
Bourdin, Arnaud
Bonniaud, Philippe
Fry, Stéphanie
Devouassoux, Gilles
Blanc, François-Xavier
Pison, Christophe
Dupin, Clairelyne
Khayath, Naji
Courdeau, Joelle
Valcke-Brossollet, Judith
Nocent-Ejnaini, Cécilia
Rolland, Fabien
Lamandi, Carmen
Proust, Alain
Ozier, Anaig
Portel, Laurent
Gaspard, Wanda
Roux-Claude, Pauline
Beurnier, Antoine
Martinez, Stéphanie
Dot, Jean-Marc
Hennegrave, Florence
Vignal, Guillaume
Auvray, Etienne
Paleiron, Nicolas
Just, Nicolas
Miltgen, Jean
Russier, Maud
Olivier, Cécile
Taillé, Camille
Didier, Alain
author_facet Guilleminault, Laurent
Camus, Claire
Raherison-Semjen, Chantal
Capdepon, Audrey
Bourdin, Arnaud
Bonniaud, Philippe
Fry, Stéphanie
Devouassoux, Gilles
Blanc, François-Xavier
Pison, Christophe
Dupin, Clairelyne
Khayath, Naji
Courdeau, Joelle
Valcke-Brossollet, Judith
Nocent-Ejnaini, Cécilia
Rolland, Fabien
Lamandi, Carmen
Proust, Alain
Ozier, Anaig
Portel, Laurent
Gaspard, Wanda
Roux-Claude, Pauline
Beurnier, Antoine
Martinez, Stéphanie
Dot, Jean-Marc
Hennegrave, Florence
Vignal, Guillaume
Auvray, Etienne
Paleiron, Nicolas
Just, Nicolas
Miltgen, Jean
Russier, Maud
Olivier, Cécile
Taillé, Camille
Didier, Alain
author_sort Guilleminault, Laurent
collection PubMed
description BACKGROUND: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. PURPOSE: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. DESIGN: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. METHODS: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. RESULTS: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. CONCLUSION: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
format Online
Article
Text
id pubmed-10655663
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106556632023-11-15 Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study Guilleminault, Laurent Camus, Claire Raherison-Semjen, Chantal Capdepon, Audrey Bourdin, Arnaud Bonniaud, Philippe Fry, Stéphanie Devouassoux, Gilles Blanc, François-Xavier Pison, Christophe Dupin, Clairelyne Khayath, Naji Courdeau, Joelle Valcke-Brossollet, Judith Nocent-Ejnaini, Cécilia Rolland, Fabien Lamandi, Carmen Proust, Alain Ozier, Anaig Portel, Laurent Gaspard, Wanda Roux-Claude, Pauline Beurnier, Antoine Martinez, Stéphanie Dot, Jean-Marc Hennegrave, Florence Vignal, Guillaume Auvray, Etienne Paleiron, Nicolas Just, Nicolas Miltgen, Jean Russier, Maud Olivier, Cécile Taillé, Camille Didier, Alain Ther Adv Respir Dis Original Research BACKGROUND: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. PURPOSE: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. DESIGN: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. METHODS: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. RESULTS: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. CONCLUSION: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma. SAGE Publications 2023-11-15 /pmc/articles/PMC10655663/ /pubmed/37966015 http://dx.doi.org/10.1177/17534666231202749 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under the terms of the Creative Commons Attribution-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits any use, reproduction and distribution of the work as published without adaptation or alteration, provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Guilleminault, Laurent
Camus, Claire
Raherison-Semjen, Chantal
Capdepon, Audrey
Bourdin, Arnaud
Bonniaud, Philippe
Fry, Stéphanie
Devouassoux, Gilles
Blanc, François-Xavier
Pison, Christophe
Dupin, Clairelyne
Khayath, Naji
Courdeau, Joelle
Valcke-Brossollet, Judith
Nocent-Ejnaini, Cécilia
Rolland, Fabien
Lamandi, Carmen
Proust, Alain
Ozier, Anaig
Portel, Laurent
Gaspard, Wanda
Roux-Claude, Pauline
Beurnier, Antoine
Martinez, Stéphanie
Dot, Jean-Marc
Hennegrave, Florence
Vignal, Guillaume
Auvray, Etienne
Paleiron, Nicolas
Just, Nicolas
Miltgen, Jean
Russier, Maud
Olivier, Cécile
Taillé, Camille
Didier, Alain
Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title_full Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title_fullStr Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title_full_unstemmed Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title_short Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
title_sort improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655663/
https://www.ncbi.nlm.nih.gov/pubmed/37966015
http://dx.doi.org/10.1177/17534666231202749
work_keys_str_mv AT guilleminaultlaurent improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT camusclaire improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT raherisonsemjenchantal improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT capdeponaudrey improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT bourdinarnaud improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT bonniaudphilippe improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT frystephanie improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT devouassouxgilles improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT blancfrancoisxavier improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT pisonchristophe improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT dupinclairelyne improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT khayathnaji improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT courdeaujoelle improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT valckebrossolletjudith improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT nocentejnainicecilia improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT rollandfabien improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT lamandicarmen improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT proustalain improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT ozieranaig improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT portellaurent improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT gaspardwanda improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT rouxclaudepauline improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT beurnierantoine improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT martinezstephanie improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT dotjeanmarc improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT hennegraveflorence improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT vignalguillaume improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT auvrayetienne improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT paleironnicolas improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT justnicolas improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT miltgenjean improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT russiermaud improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT oliviercecile improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT taillecamille improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy
AT didieralain improvementinsevereasthmapatientsreceivingbiologicsandfactorsassociatedwithpersistentinsufficientcontrolareallifenationalstudy